Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
veliparib + bortezomib
- Development stage
- Unknown
- Lead developer
- AbbVie
- Modality
- Small Molecules
- Administration
- Oral, Intravenous, Subcutaneous
01
Overview
Veliparib + bortezomib is an investigational combination therapy consisting of two small molecule drugs with distinct mechanisms of action, primarily explored in oncology. Veliparib (ABT-888) is a poly(ADP-ribose) polymerase (PARP) inhibitor that impairs DNA repair in cancer cells, leading to cell death, especially in tumors with existing DNA repair deficiencies. Bortezomib (marketed as Velcade and Boruzu; code names PS‑341 and MLN‑341) is a reversible inhibitor of the 26S proteasome, disrupting protein degradation pathways within cells and inducing apoptosis by causing accumulation of misfolded or damaged proteins. Bortezomib is approved for the treatment of multiple myeloma and mantle cell lymphoma[2][5][8]. The combination has been studied for potential synergistic effects in various cancers due to their complementary mechanisms—veliparib targeting DNA repair and bortezomib targeting protein homeostasis.
- Brand names
- Boruzu
- Other names
- veliparib + bortezomib
02
Targets
PSMB5 (Proteasome subunit beta Type-5)PSMB1 (26S Proteasome (β1-Subunit))PARP2 (Poly (adp-ribose) polymerase 2)
Beyond the preview
Go deeper on veliparib + bortezomib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on veliparib + bortezomib.